Results 141 to 150 of about 659,948 (302)
Genetic and Pathological Testing Attitudes for Parkinson's Disease in At‐Risk Relatives
Movement Disorders Clinical Practice, EarlyView.Abstract Background Parkinson's disease (PD) is increasingly recognized as a neurodegenerative disorder with a broad clinical spectrum and diverse biomarkers enabling early detection. α‐synuclein seed amplification assays (SAA) and genetic testing now allow identification of PD pathology in asymptomatic individuals.
Tal Weil +5 more
wiley +1 more source
Quantitative Assessment of Visible Nigrosome‐1 in Patients with Parkinson's Disease
Movement Disorders Clinical Practice, EarlyView.Abstract Background The nigrosome‐1 (N1) sign on susceptibility‐weighted imaging (SWI) typically disappears in Parkinson's disease (PD), though some patients can show uni−/bilaterally preserved N1. Objective Investigating whether visible nigrosomes in PD patients differ from those of healthy subjects (HC). Methods Forty‐eight PD and 35 HC underwent 3 T‐
Maria Eugenia Caligiuri +10 more
wiley +1 more source
A novel molecular mechanism for nitrated alpha-synuclein-induced cell death
, 2011 Although previous studies have demonstrated the involvement of nitrated alpha-synuclein in neurodegenerative disorders (synucleinopathies), the effects of nitrated alpha-synuclein and the molecular mechanisms underlying its toxicity are still unclear. In
Qiang, Min +4 more
core
Movement Disorders Clinical Practice, EarlyView.Abstract Background Visuospatial deficits in Parkinson's disease (PD) often precede dementia and complicate daily functioning. Alzheimer's disease (AD) pathology and α‐synuclein aggregation frequently co‐occur in PD, but their combined impact on cognition is unclear.
David Ledingham +8 more
wiley +1 more source
Potential Modes of Intercellular Alpha-Synuclein Transmission
, 2017 Intracellular aggregates of the alpha-synuclein protein result in cell loss and dysfunction in Parkinson’s disease and atypical parkinsonism, such as multiple system atrophy and dementia with Lewy bodies.
Dario Valdinocci +4 more
core +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Non‐motor symptoms, especially autonomic dysfunction, are major contributors to disability and decreased quality of life in Parkinson's disease (PD). Despite being common and having a wide range of clinical facets, exocrine gland dysfunction is still not well recognized and managed.
Renato P. Munhoz +2 more
wiley +1 more source
Caenorhabditis elegans as an Experimental Model Organism to Study Parkinson's Disease-Related Genes [PDF]
, 2005 Parkinson’s disease (PD) is the second most common neurodegenerative disorder, mainly characterized by motor dysfunctions resulting from massive and selective loss of dopaminergic neurons. Mutations in the human parkin gene, which encodes an E3 ubiquitin
Springer, Wolfdieter
core
Movement Disorders Clinical Practice, EarlyView.Abstract Background LRRK2‐Parkinson's disease (LRRK2‐PD) is biologically heterogeneous with approximately 30% lacking aggregated alpha synuclein (αSyn) in cerebrospinal fluid by seed amplification assay (SAA). Prior work has suggested slower progression in LRRK2‐PD compared to sporadic PD (sPD).
Lucy A. Morse +224 more
wiley +1 more source
Homogenous Cell Transplantation Trials in Parkinson's Disease: A Systematic Review and Meta‐Analysis
Movement Disorders Clinical Practice, EarlyView.Abstract Background The transplantation of homogenous cells has emerged as an investigational strategy for Parkinson's disease (PD), offering an alternative to symptomatic treatment. Objective We performed a systematic review and meta‐analysis to assess its clinical efficacy and safety.
Nolan Reinisch +4 more
wiley +1 more source